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2Abstract
Objective
To confirm the presence of subclinical cardiovascular dysfunction in working-age 
adults with type 2 diabetes (T2D) and determine if this is improved by a low-energy 
meal replacement diet (MRP) or exercise training.
Research design and Methods
Prospective, randomized, open-label, blinded-endpoint trial with nested case-control 
study. Asymptomatic younger adults with T2D were randomized 1:1:1 to a 12-week 
intervention of: 1) routine care; 2) supervised aerobic exercise training or 3) a low-
energy 2B>;:!C
3 MRP. Participants underwent echocardiography, 
cardiopulmonary exercise testing and cardiac magnetic resonance imaging (CMR) at 
baseline and 12-weeks. The primary outcome was change in left ventricular (LV) 
peak early diastolic strain rate (PEDSR), measured by CMR. Healthy volunteers were 
enrolled for baseline case-control comparison.
Results
Eighty-seven participants with T2D (age 51±7y, HbA1c 7.3±1.1%) and 36 matched 
controls were included. At baseline, those with T2D had evidence of diastolic 
dysfunction (PEDSR 1.01±0.19 vs. 1.10±0.16s-1, p=0.02) compared with controls. 
Seventy-six participants completed the trial (30 routine care, 22 exercise, and 24 
MRP). The MRP arm lost 13kg in weight, improved blood pressure, glycemia, LV 
mass/volume and aortic stiffness.  The exercise arm had negligible weight loss but 
increased exercise capacity. PEDSR increased in the exercise arm versus routine care 
2IH:/;4 p=0.002), but did not improve with the MRP 2IH:/:;< p=0.731).
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3Conclusions
In asymptomatic working-age adults with T2D, exercise training improved diastolic 
function. Despite beneficial effects of weight loss on glycemic control, concentric LV 
remodelling and aortic stiffness, a low-energy MRP did not improve diastolic 
function.
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4Abbreviations
CMR=cardiovascular magnetic resonance
HOMA-IR=homeostatic model assessment-insulin resistance
LV=left ventricle
MRP=meal replacement plan
NICE=National Institute for Health and Care Excellence
NIHR=National Institute for Health Research
PEDSR=peak early diastolic strain rate
T2D=type 2 diabetes mellitus
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5The likelihood of developing cardiovascular disease is markedly increased in younger 
adults with type 2 diabetes mellitus (T2D), who have the highest lifetime risk(1). The 
United Kingdom National Diabetes Audit 2015-16, which includes data on over 2.7 
million people with diabetes, found that heart failure is the commonest cardiovascular 
complication of type 2 diabetes (T2D) and a major cause of premature mortality(2). 
This is especially the case in younger adults with T2D, where the risk of heart failure 
development is four- to five-fold higher than matched controls(1). Importantly, 
undiagnosed heart failure is highly prevalent (present in up to one third) in people 
with T2D(3). We have previously demonstrated evidence of subclinical diastolic 
impairment in young adults (mean age 32 years) with T2D, despite their young age 
and relatively short duration of disease(4).
Whilst the risk of atherosclerotic cardiovascular disease can be mitigated by 
strict risk factor management in T2D, this has little to no effect on the excess risk of 
heart failure(5). Therefore, the development of effective therapies to prevent and treat 
heart failure in people with T2D represents an important unmet need in this 
population.
Reversal of T2D can be achieved with weight loss, accomplished either by 
bariatric surgery(6) or via a low-energy meal replacement plan diet (MRP)(7). 
Exercise training also leads to modest but sustained improvements in glycemic 
control, improvements in insulin resistance, and improved cardiovascular fitness, 
even in the absence of accompanying weight loss(8,9). Whether weight loss or 
exercise training can improve subclinical cardiac dysfunction in people with T2D 
remains to be established. There have been no randomized controlled trials assessing 
cardiac function with a MRP and the results of trials in exercise training have been 
inconsistent(10). 
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6The aims of this study were: (1) to confirm the presence and nature of 
subclinical cardiovascular dysfunction in working-age adults with T2D, and (2) to 
determine if diastolic function can be improved by either a low-energy MRP or a 
supervised aerobic exercise programme, compared to routine care.
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Study design
The rationale and study design and conduct, including details of participant 
recruitment and planned analyses, have been published previously(11). In brief, this 
was a single-centre prospective, randomized, open-label, blinded-endpoint trial with a 
nested case-control study, at the National Institute for Health Research (NIHR) 
Leicester Biomedical Research Centre. Ethical approval was granted by the National 
Research Ethics Service (15/WM/0222). The trial is registered at 
https://clinicaltrials.gov (unique identifier: NCT02590822).
Participants
Eligible participants were aged 18 to 65 years, with established T2D (duration L4 
months) diagnosed before age 60 years and BMI >30kg/m2 (or >27kg/m2 if South 
Asian or Black ethnicity). Key exclusion criteria were T2D duration >12 years, 
current treatment with >3 glucose-lowering medications or insulin, history, signs or 
symptoms of cardiovascular disease (including coronary artery disease, stroke, 
transient ischemic attack, peripheral artery disease or heart failure), weight loss >5kg 
in the preceding six months, and inability to exercise or undertake the MRP. A list of 
the complete study inclusion and exclusion criteria is provided in the protocol(11). 
Healthy volunteers free of T2D, obesity, hypertension, or prevalent cardiovascular 
disease were recruited for baseline case-control comparison. All participants provided 
written informed consent.
Participants with T2D underwent two main study assessment visits, at baseline 
and 12 weeks (see below). Control subjects underwent the same assessments, but at 
baseline only. 
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8Randomization and blinding
Subjects with T2D were randomised at the end of the baseline visit in a 1:1:1 ratio, 
using an independent online computerised randomization system incorporating 
concealed allocation (Sealed Envelope®) to one of three arms: 1) routine care as per 
National Institute for Health and Care Excellence (NICE) guidance(12), 2) a 
supervised aerobic exercise programme or 3) a low-energy 2B>;:!C
3 MRP diet.  
Randomization was stratified by sex and baseline glucose-lowering therapy (any 
glucagon-like peptide-1 agonist, dipeptidyl peptidase-IV inhibitor or sodium glucose 
cotransporter 2 inhibitor versus none of these agents). The nature of the trial 
interventions prevented blinding of allocation.
Assessments
Demographics, medical history and anthropometric measures were collected at the 
assessment visits. A fasting blood sample was collected to obtain a biochemical 
profile for diabetes control, liver and kidney function, lipid profile, adiposity, insulin 
and C-peptide. Insulin resistance was estimated using the homeostatic model 
assessment-insulin resistance method (HOMA-IR)(13). Participants in the MRP arm 
with a fasting glucose of <7.0mmol/L or HbA1c <6.5% without taking any 
hypoglycemic agent post-intervention were considered to have remission of T2D(14). 
Cardiovascular magnetic resonance imaging
Comprehensive cardiovascular magnetic resonance (CMR) scanning was performed 
on a 1.5T field strength scanner (Siemens Aera, Erlangen, Germany) using a 
standardised protocol(11). CMR images were analysed offline blinded to all patient 
details and treatment group. Cardiac chamber volumes, function and strain were 
assessed by a single experienced observer (G.S.G) using cmr42 version 5 (Circle 
Cardiovascular Imaging, Calgary, Alberta, Canada).
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9Transthoracic echocardiography
Transthoracic echocardiography was performed and interpreted by two accredited 
operators (A-M.M and J.M.) using an iE33 system with S5-1 transducer (Philips 
Medical Systems, Best, The Netherlands). Images were acquired and reported as per 
American Society of Echocardiography guidelines(15). Early diastolic transmitral 
flow velocities (E) and early diastolic mitral annular velocities (e) to estimate LV 
filling pressures were assessed by Doppler echocardiography per current 
recommendations(16).
Cardiopulmonary exercise testing
A symptom-limited incremental cardiopulmonary exercise test was performed on a 
stationary electromagnetically braked cycle ergometer (eBike, General Electric 
Healthcare, Bedford, UK) with expired gas analysis (Ganshorn PowerCube, General 
Electric Healthcare, Bedford, UK) to determine peak oxygen consumption (VO2)(17).
Trial interventions
Routine care
Standard lifestyle advice was provided in a single coaching interview at week 0, along 
with signposting to freely available NHS resources in accordance with NICE 
guidance(12). Optimisation of blood pressure and glucose-lowering medications was 
undertaken by a study clinician at baseline in accordance with NICE guidance(12).
Supervised exercise programme
Participants attended thrice weekly, supervised moderate-intensity aerobic exercise 
sessions. Exercise sessions consisted of a warm-up, stimulus and cool-down phase. 
The stimulus phase included walking and/or lower extremity cycling. Exercise 
intensity was titrated to B<:G baseline peak VO2 and heart rate. The total exercise 
duration was gradually increased to achieve a target of 50 minutes per session. 
Objective (heart rate monitoring) and subjective (Borg Rate of Perceived Exertion 
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Scale) measures were used to evaluate the response to exercise sessions and to adjust 
exercise intensity in accordance with increasing fitness levels throughout the 
intervention period. Compliance was assessed by attendance at the supervised 
exercise sessions. Participants who attended less than two-thirds of the exercise 
sessions were considered non-compliant and excluded from the study. Participants 
were asked to maintain their usual dietary intake.
Low energy MRP diet
The low-energy MRP comprised an average of B>;:!C
 (30% protein, 50% 
carbohydrate and 20% fat) (Cambridge Weight Plan®). Participants were asked to 
discontinue all glucose-lowering therapies following randomization to avoid 
hypoglycemia. Antihypertensive medications were stopped on the day of 
commencement. Blood pressure and glucose were monitored throughout the study by 
a study clinician. Participants were advised to maintain their usual daily activities 
while on the diet and asked not to initiate any additional physical activity for the 
duration of the intervention. The diet was discontinued and a maintenance diet 
introduced once 50% excess body weight had been lost, or by 12 weeks, whichever 
came first. Those participants who did not achieve a loss of >2% body weight at week 
1 and 4% at week 3 were considered non-compliant and were excluded from the 
study.
Outcomes
The primary outcome was a measure of diastolic function: change in left ventricular 
peak early diastolic strain rate (LV PEDSR, an index of the speed of myocardial 
relaxation), measured by CMR, from baseline to 12 weeks, in the two intervention 
arms (MRP diet and exercise) compared to routine care. Key secondary outcomes 
were change in echocardiographic measures of diastolic function (E/A ratio and E/e). 
Additional secondary outcomes were CMR measures of cardiac structure and function 
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(LV mass and volumes, global longitudinal strain) myocardial perfusion reserve, 
aortic stiffness (distensibility) and peak oxygen consumption(11).
Power calculation
The trial sample size calculation was determined according to published pilot data 
from our group(4). To detect a between-group difference in PEDSR of 0.2s-1 post-
interventions, at least 21 participants with T2D completing each of the three trial arms 
were needed to provide 80% power, at alpha=0.025 (to allow for two primary 
comparisons, i.e. MRP vs. routine care and exercise vs. routine care). Assuming a 
maximum dropout rate of 30%, we targeted recruitment of 30 patients per group at 
baseline.
Statistical analysis 
Statistical analyses were performed by an independent trial statistician (NBJ) at the 
Leicester Clinical Trials Unit. Normality was assessed using histograms, the Shapiro-
Wilk test and Q-Q plots. Continuous data are expressed as mean (± standard 
deviation), if normally distributed or median (25-75% interquartile range) if not. At 
baseline, patients and control groups were compared by independent t-tests or Mann-
Whitney tests as appropriate. Categorical variables were compared using the Chi-
squared test or Fishers exact test as appropriate. For the analysis of the primary 
outcome, each intervention was compared with the routine care arm using linear 
regression adjusted for stratification factors (sex and baseline glucose lowering 
therapy) and baseline PEDSR. The treatment effect was presented as a point estimate, 
confidence interval and p-value. Changes in the key secondary outcomes (E/A ratio 
and E/e) were also assessed using linear regression with the same stratification 
factors as the primary outcome. Given the large number of additional secondary 
outcomes, formal statistical testing was not undertaken on these parameters but 
changes between baseline and follow-up are presented with 95% confidence intervals. 
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Statistical analysis was done using Stata software, version 15 (StataCorp LLC, Texas, 
USA).
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Results
The trial profile displayed in supplementary figure 1. Between November 2015 and 
May 2018, 260 patients were screened, of whom 93 consented and enrolled. Three 
were found to be ineligible after consent and 90 subjects were randomized: 30 to 
routine care, 31 to the supervised exercise programme and 29 to the MRP diet. Three 
of these participants (two in the exercise arm and one in the MRP arm) were found to 
be ineligible after laboratory test results became available and did not undertake the 
intervention. A total of 76 patients with T2D completed the trial (30 in the routine 
care arm, 22 in the exercise arm and 24 in the MRP arm). Reasons for discontinuation 
are shown in supplementary figure 1. Thirty-nine healthy volunteers were enrolled for 
baseline case-control comparison. Three of these were subsequently excluded (one 
due to the presence of obesity and two who were unable to undergo CMR scanning 
due to claustrophobia). A total of 36 healthy volunteers were therefore included in 
case-control comparisons.
Baseline characteristics
The baseline demographic characteristics of subjects with T2D and controls are 
shown in table 1. Mean age of participants with T2D was 50.5±6.5 years, mean body 
mass index was 36.6±5.5 kg/m2, mean duration of diabetes was 5.4±3.2 years, 41% 
were women, and 37% were from a minority ethnic group. The control group were 
similar for age, sex and ethnicity, but had lower overall body weight and body mass 
index. Among those with T2D, 43% had a history of smoking and 52% had a history 
of hypertension. None of the control subjects had a history of hypertension or 
dyslipidemia. Antihypertensive and lipid-lowering medication use was therefore 
higher in those with T2D compared to controls.
Fasting blood test results are displayed in table 1. Both T2Ds and healthy 
controls had similar renal function. Subjects with T2D had higher overall glycated 
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hemoglobin (7.3±1.0 vs. 5.4±0.2%, p<0.001), lower total cholesterol (4.6±1.0 vs. 
5.7±0.8mmol/L, p<0.001) and LDL cholesterol (2.4±0.8 vs. 3.3±0.8mmol/L, 
p<0.001) than controls, respectively. Adiponectin levels were significantly lower and 
leptin levels significantly higher (both p<0.001) in T2Ds versus controls. Fasting C-
peptide and insulin levels were significantly higher (both p<0.001) in T2Ds compared 
with controls. Similarly, overall HOMA-IR was higher in T2Ds versus controls (9.2 
[6.2  13.5] vs. 1.6 [1.1  2.5], respectively, p<0.001). B-natriuretic peptide levels 
were significantly lower in the T2D group compared to controls (10.6 [4.5  17.9] vs. 
16.0 [8.7  22.6] ng/L, respectively, p=0.048).
Cardiovascular differences between T2Ds and controls
Baseline CMR imaging, cardiopulmonary exercise testing, and echocardiography data 
comparing T2Ds and controls are displayed in table 1. Left ventricular PEDSR was 
significantly lower in T2Ds compared to controls (1.01±0.19 vs. 1.10±0.16, p=0.02). 
Subjects with T2D also had smaller indexed LV volumes, higher LV ejection fraction, 
and higher LV mass than controls. In those with T2D, there was increased concentric 
LV remodelling (LV mass:volume 0.82±0.12 vs. 0.71±0.10g/mL, p<0.001) and lower 
mean aortic distensibility (4.16±2.05 vs. 6.56±2.02mmHg-1x10-3, p<0.001) than 
controls. There were no significant differences in indexed LV mass or global 
longitudinal strain between groups. Myocardial perfusion reserve was lower in T2Ds 
compared with controls.
Complete echocardiographic transmitral flow velocities were measurable in 84 
subjects with T2D and all 36 controls. Mean E/A ratio was significantly lower in the 
T2D group compared with controls (0.95±0.21 vs. 1.21±0.25, p<0.001). Mitral 
annular velocities were measureable in 78 individuals with T2D and all 36 controls. 
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Overall, average E/e was higher in those with T2D compared to the control group 
(8.1 [6.2  9.6] vs. 62. [5.0  7.8], p<0.001) (table 1).
All measures of cardiorespiratory fitness (maximum workload achieved, 
absolute and body-weight corrected peak oxygen uptake) were lower in the T2Ds 
versus controls (table 1). 
Prospective, randomised, open-label, blinded-endpoint trial
The baseline demographic characteristics and prescribed diabetes and anti-
hypertensive medications of participants stratified by treatment arm in the trial are 
shown in supplementary table 1. The three groups were well balanced.
Changes in bio-anthropometric measures, physical activity and cardiorespiratory 
fitness indices with interventions
Changes from baseline to 12 weeks in anthropometric measures, biochemical 
parameters, and cardiorespiratory fitness in subjects who completed the study are 
shown in table 2. 
In the routine care arm, body weight remained stable and there were no 
significant changes in body composition measures (body mass index and waist-to-hip 
ratio). Markers of insulin resistance and glycemic control remained similar from 
baseline to 12 weeks. Mean systolic blood pressure dropped by 7mmHg, driven by a 
guideline-directed increase in the doses of existing prescribed antihypertensive 
medications. Cardiopulmonary fitness did not change by the end of the trial period.
In the exercise programme arm there were small non-significant reductions in body 
weight (median weight loss 1.6kg) and body mass index (median reduction 0.8kg/m2). 
There was no significant change in glycemic control, insulin resistance or blood 
pressure. Although there was no significant change in peak oxygen uptake by week 
12, subjects total exercise duration and maximum workload achieved did increase 
(by 1.2 mins and 22 Watts, respectively).
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In the MRP arm, median weight loss was 13.6kg, body mass index fell by 
4.8kg/m2, and mean systolic blood pressure dropped by 13mmHg, despite a reduction 
in the number and/or dose of anti-hypertensives taken. Median HbA1c decreased by 
0.75% (7.5mmol/mol), with 20 (83%) participants achieving T2D remission. There 
was a non-significant trend for adiponectin to increase and median leptin decreased 
by 9,873pg/mL, median HOMA-IR decreased by 6 units, and median brain natriuretic 
peptide increased by 3.5ng/L. There was a small increase in peak oxygen uptake when 
corrected for body weight (1.9mL/kg/min), but not in absolute peak oxygen uptake. 
Other measures of cardiorespiratory fitness did not change.  
Primary and key secondary cardiac outcomes
Changes in the primary endpoint from baseline to 12 weeks are displayed in figure 1. 
For the primary outcome measure, participants in the supervised exercise programme 
arm demonstrated a significant improvement in PEDSR compared to those in the 
routine care arm of the trial 2IH:/;4 97.5% CI 0.038 to 0.225, p=0.002). No 
improvement in PEDSR was observed in participants in the MRP arm versus those in 
the routine care arm of the trial 2IH:/:;< 97.5% CI -0.075 to 0.106, p=0.731).
Average E/e and early diastolic to late filling ratio (E/A) ratio could be 
obtained in 63 (83%) and 70 (92%) of participants who completed the trial, 
respectively. E/A ratio and non-invasive assessment of filling pressure (E/e) tended 
to improve in both intervention arms, but these changes were not statistically 
significant compared to the routine care arm: average E/e in the exercise arm of the 
trial versus the routine care arm at 12 weeks IH,:/9=5 95% CI -1.452 to 0.534, 
p=0.355, and E/A ratio IH:/:> 95% CI -0.086 to 0.142, p=0.621. Similarly, there 
was no difference in average E/e in the MRP arm versus routine care at 12 weeks 
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2IH,:/:<: 95% CI -1.099 to 0.978, p=0.907), or E/A ratio 2IH:/:4< 95% CI -0.090 
to 0.161, p=0.568).
Key secondary cardiac imaging endpoints at baseline and 12 weeks in the 
three trial arms are displayed in table 3. In the routine care arm and the exercise arm 
there were negligible changes in most cardiac parameters. In the MRP arm there was 
a trend towards a reduction in LV mass (mean reduction 5.6grams) and indexed LV 
end diastolic volume increased by 5mL/m2, with a corresponding significant reduction 
in concentric LV remodelling (mean change -0.03g/mL, 95% CI -0.06 to -0.01). 
Aortic distensibility increased by 0.90mmHg-1x10-3 (95% CI 0.38 to 1.41). With 
regards to systolic function there was a significant lowering of ejection fraction (-
1.32%, 95% CI -0.27 to -2.37) in the MRP arm. There were no significant changes in 
myocardial perfusion reserve in any group.
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Discussion
This is the first randomized controlled trial to compare the effects on cardiac structure 
and function of a low-energy diet versus an aerobic exercise programme or routine 
care in working-age adults with T2D. Compared with controls, individuals with T2D 
had reduced diastolic function, increased concentric LV remodelling, reduced 
myocardial perfusion, and increased aortic stiffening, consistent with asymptomatic 
stage B heart failure(18). A 12-week supervised aerobic exercise training programme 
led to favourable improvements in diastolic function in the absence of any major 
effects on LV remodelling, perfusion or aortic stiffening. Despite beneficial effects 
observed on glycometabolic profile, blood pressure, aortic stiffness and concentric 
LV remodelling, a low-energy MRP diet did not lead to improved diastolic function. 
Our T2D cohort may already have stage B heart failure(18), with clear 
evidence of reduced diastolic function by both CMR and echocardiographic measures. 
Diastolic dysfunction and concentric LV remodelling are typically the earliest 
manifestations of diabetic cardiomyopathy, and likely precursors to the onset of 
clinical heart failure(19). Our results suggest that supervised aerobic exercise training 
may improve the earliest functional consequence of T2D on the myocardium. 
Subjects with T2D had markedly lower aerobic exercise capacity compared to 
controls at baseline, and beneficial effects on diastolic function were observed even 
when only accompanied by small improvements in fitness.
Several studies have assessed the effects of various exercise interventions on 
diastolic function in people with T2D, predominantly using echocardiography(10). In 
general, these have shown that exercise training has favourable effects on diastolic 
function, although with inconsistent results, likely due to differences in study 
populations, modes of exercise intervention, and various measures of diastolic 
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function being employed. Although we did not see any significant improvement in 
echocardiographic measures of diastolic function, resting measures may not have 
adequate sensitivity(20). This is especially true in a population who have obesity, 
such as ours; with a higher likelihood of poor echocardiographic windows. Almost 
20% of our patients did not have sufficient windows for accurate measurement of 
diastolic function by echocardiography.
The mechanism of benefit of aerobic exercise on diastolic function in our 
cohort is unclear. We did not observe significant improvements in myocardial 
perfusion or cardiac remodelling with exercise, although the study was not powered to 
detect these outcomes. It is posited that exercise interventions cause improvements in 
myocyte calcium handling, mitochondrial function, inflammation and energy 
metabolism(10,21,22), which are linked to impaired cardiac contraction and 
relaxation(23). We were not able to assess these parameters in the current study, but 
given the lack of improvement in cardiac energetics following 12-weeks of high 
intensity interval training in a previous study in people with T2D(24), it seems this 
mechanism is unlikely to explain the benefit observed in diastolic function.  
The ability to achieve remission of T2D by weight loss with administration of 
low-energy MRP diet was convincingly demonstrated in the DiRECT trial(7). 
However, improvements in cardiac function after weight loss in T2D have not been 
studied in a randomised controlled trial setting previously. Administration of a low-
energy MRP diet in our patients led to dramatic improvements in body weight, blood 
pressure and resting heart rate, fasting triglycerides, HbA1c, and markers of insulin 
resistance, mirroring the findings of the DiRECT trial(7). We also observed similar 
rates of remission of T2D to those in the DiRECT trial. However PEDSR did not 
change after MRP and we observed a reduction in LV ejection fraction with a small 
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rise in brain natriuretic peptide levels. It is recognised that obesity is associated with 
increased sympathetic activity, which may result in hyperdynamic LV function(25). 
This is supported by our finding that LV ejection fraction was higher at baseline in 
those with T2D compared to healthy weight controls. The observed reduction in 
ejection fraction in the MRP arm may, therefore, reflect normalisation of 
hyperdynamic LV function with weight loss. Furthermore, obesity and T2D are both 
known to lower brain natriuretic peptide levels and its increase in the MRP arm of the 
trial is also likely to be a consequence of the weight loss(26,27).
Our interpretation is that diastolic dysfunction may be irreversible with 
improvements in glycometabolic derangements alone. Supporting evidence includes 
data from interventional trials that have not shown reductions in heart failure risk with 
strict glycemic control(28). Although diastolic function did not improve, we did 
observe modest changes in cardiac remodelling and aortic distensibility in the MRP 
arm of the trial. Given that LV hypertrophy and smaller LV volumes are typically 
seen in diabetic cardiomyopathy (which was confirmed by our case-control analysis) 
and are associated with poorer cardiovascular outcomes(29,30), these changes may 
indicate favourable long-term effects of the dietary restriction or weight loss on the 
structural manifestations of heart failure in T2D. Furthermore, we have previously 
shown that aortic stiffening is an independent determinant of concentric LV 
remodelling(31) and the observed increase in aortic distensibility with MRP suggests 
that weight loss may ameliorate vascular stiffness in T2D and could prompt reverse 
cardiac remodelling. It is possible that the best approach for improving stage B heart 
failure in people with T2D is a combination of exercise and dietary restriction to 
achieve weight loss, given the different effects of these interventions on diastolic 
function and cardiac remodelling in our study. Further trials are needed to assess the 
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cardiovascular effects of combined exercise with dietary restriction and weight loss in 
people with T2D and for longer durations.  
Key strengths our trial were the randomization of participants to interventions 
with blinded analyses and the comprehensive cardio-metabolic phenotyping that 
subjects underwent. Although the younger, working-age population in this study have 
the highest lifetime risk of heart failure, they are under-represented in large-scale 
cardiovascular outcomes trials of T2D, and no studies have demonstrated effective 
therapies to prevent or treat heart failure in this group. 
Our trial also has some limitations, including the unblinded design, with 
ascertainment bias eliminated as far as possible with blinding of all imaging 
parameters, and the short duration of follow-up. The exclusion criteria were set to 
maximise the probability of remission of T2D with the MRP and therefore the results 
are not generalizable to the entire population with T2D. The effects of sustained 
weight loss on cardiac structure and function were not assessed, nor the possibility 
that de-training could lead to worsening of diastolic function in those who undertook 
the supervised exercise arm of the trial. Although we achieved the necessary 
statistical power for our trial, the relatively high rate of non-compliance (19%) with 
the supervised exercise intervention may hinder its real-world application.
Conclusions
In working-age adults with T2D and obesity without prevalent cardiovascular disease, 
there is already evidence of subclinical diastolic dysfunction, concentric LV 
remodelling and aortic stiffening. A 12-week supervised aerobic exercise training 
programme led to improvements in LV diastolic function without major effects on 
cardiac remodelling, weight loss, blood pressure, or glycemic control. Conversely, a 
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low-energy MRP diet led to improvements in glycometabolic profiles, concentric LV 
remodelling and aortic stiffness, but did not improve measures of diastolic function.
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Tables
Table 1. Baseline bio-anthropometrics, cardiac MRI, cardiopulmonary exercise 
testing and echocardiographic data in subjects with T2D versus controls.
T2D (n=87) CONTROLS (n=36) P-value
DEMOGRAPHICS
Age, years 50.5±6.5 48.6±6.2 0.15
Sex, n (%)
   Male 51 (59) 19 (53)
   Female 36 (41) 17 (47)
0.552
Ethnic origin, n (%)
   Caucasian 55 (63) 25 (69)
   Black or other minority ethnicity 32 (37) 11 (31)
0.51
ANTHROPOMETRICS
Height, cm 168±10 169±9 0.54
Weight, kg 103.3±16.7 70.4±10.8 <0.001
Body mass index, kg/m2 36.6±5.5 24.5±2.4 <0.001
Systolic blood pressure, mmHg 140±15 121±13 <0.001
Diastolic blood pressure, mmHg 87±8 76±7 <0.001
Heart rate, beats/min 74±10 62±10 <0.001
MEDICAL HISTORY
Diabetes duration, months 56 (32  94) N/A N/A
Smoking history, n (%) 39 (45) 9 (25) <0.001
Hypertension, n (%) 44 (51) 0 (0) <0.001
Dyslipidemia, n (%) 56 (64) 0 (0) <0.001
MEDICATIONS
ACE inhibitor, n (%) 28 (32) 0 (0) <0.001
ARB, n (%) 11 (13) 0 (0) 0.025
Beta blocker, n (%) 6 (7) 0 (0) 0.106
Calcium channel blocker, n (%) 19 (22) 0 (0) 0.002
Statin, n (%) 58 (67) 0 (0) <0.001
Metformin, n (%) 82 (94) N/A N/A
Sulfonylurea, n (%) 13 (15) N/A N/A
DPP-IV inhibitor, n (%) 17 (20) N/A N/A
SGLT2 inhibitor, n (%) 10 (11) N/A N/A
GLP-1 receptor agonist, n (%) 10 (11) N/A N/A
FASTING BLOOD TESTS
Urea, mmol/L 5.4±1.2 5.2±1.4 0.59
Creatinine, mmol/L 76±15 79±12 0.332
Estimated GFR, mL/min 90 (80 - 90) 85 (78 - 90) 0.122
Glucose, mmol/L 7.6 (6.6 - 10.1) 5.0 (4.6 - 5.2) <0.001
HbA1c, % 7.3±1.0 5.4±0.2 <0.001
HbA1c, mmol/mol 56±11 35±3 <0.001
Total cholesterol, mmol/L 4.6±1.0 5.7±0.8 <0.001
Triglycerides, mmol/L 1.88 (1.18 - 2.74) 0.98 (0.72 - 1.54) <0.001
HDL, mmol/L 1.2 (1.0 - 1.4) 1.7 (1.6 - 2.0) <0.001
LDL, mmol/L 2.4±0.8 3.3±0.8 <0.001
Cholesterol:HDL 3.9±0.9 3.3±0.8 <0.001
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Hemoglobin, g/L 144±16 141±14 0.279
Adiponectin, ng/L 3460 (2550 - 5652) 9514 (4820 - 14589) <0.001
Leptin, pg/L 18911 (9821 - 34115) 4811 (2400 - 9818) <0.001
C-peptide, ng/L 2591 (1865 - 3371) 969 (743 - 1199) <0.001
Insulin, miu/L 26.5 (18.8 - 35.8) 7.4 (4.9 - 10.4) <0.001
HOMA-IR 9.2 (6.2 - 13.5) 1.6 (1.1 - 2.5) <0.001
B-natriuretic peptide, ng/L 10.6 (4.5 - 17.9) 16.0 (8.7 - 22.6) 0.048
CARDIAC MRI
LV EDVi, mL/m2 67±10 83±19 <0.001
LV EF, % 68±7 65±5 0.016
LV mass, g 121±25 107±32 0.011
LV mass index, g/m2 55±9 58±14 0.133
LV mass:volume, g/mL 0.82±0.12 0.71±0.10 <0.001
LV global longitudinal strain, % U;</5E/< U;F/<E;/= 0.179
LV PEDSR, s-1 1.01±0.19 1.10±0.16 0.02
Myocardial perfusion reserve 3.02±0.98 3.98±1.01 <0.001
Aortic distensibility, mmHg-1x10-3 4.16±2.05 6.56±2.02 <0.001
ECHOCARDIOGRAPHY
E/A ratio 0.95±0.21 1.21±0.25 <0.001
Average E/e' 8.1 (6.2 - 9.6) 6.2 (5.0 - 7.8) <0.001
CARDIOPULMONARY EXERCISE TESTING
Maximum workload achieved, W 125±47 173±67 <0.001
Peak VO2, mL/kg/min 16.6±4.1 27.5±8.2 <0.001
Peak VO2, L/min 1.70±0.46 1.96±0.73 0.019
Data are n (%), mean±SD, or median (IQR). Abbreviations: ACE=angiotensin 
converting enzyme; ARB=angiotensin receptor blocker; GLP-1=glucagon-like 
peptide-1; DPP-IV=dipeptidyl peptidase-IV; SGLT2=sodium glucose cotransporter-2; 
HOMA-IR=homeostatic model assessment of insulin resistance, LV=left ventricle; 
EDVi=end-diastolic volume indexed to body surface area; EF=ejection fraction; 
PEDSR=peak early diastolic strain rate. 
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Table 2. Bio-anthropometric measures at baseline, 12 weeks and change from baseline to 12 weeks in the three trial arms.
Routine care (n=30) Exercise (n=22) MRP (n=24)
Baseline Week 12 Median change 
(95% CI)
Baseline Week 12 Median change 
(95% CI)
Baseline Week 12 Median change 
(95% CI)
Anthropometrics
Weight (kg) 102·6 (14·9) 100·4 (14·5) -1.05 (-3.16, -
0.01)
99·2 (16·3) 97·8 (16·6) -1.55 (-2.51, -
0.48)
106·7 (16·2) 93·0 (15·0) -13.55 (-15.53, -
11.90)
Body mass index  
(kg/m2)
35·0 (33·0 - 40·7) 34·5 (32·0 - 41·0) -0.25 (-1.00, 0.00) 33·0 (31·8 - 
35·0)
33·0 (31·0 - 
34·7)
-0.75 (-1.00, -
0.09)
35·2 (33·5 - 40·3) 30·3 (28·1 - 35·5) -4.75 (-5.17, -
4.00)
Systolic BP (mmHg) 137·8 (12·7) 130·8 (14·4) -7.07 (-10.60, -
3.54)*
135·5 (16·9) 133·0 (14·3) -2.45 (-8.94, 
4.03)*
145·9 (15·9) 132·9 (18·0) -13.00 (-21.60, -
4.40)*
Diastolic BP (mmHg) 85·3 (7·3) 83·5 (10·2) -1.83 (-4.65, 
0.99)*
87·2 (8·2) 86·7 (8·5) -0.55 (-4.08, 
2.98)*
91·1 (7·4) 86·5 (9·1) -4.67 (-9.50, 
0.17)*
Heart rate (bpm) 76·3 (7·5) 73·3 (9·6) -3.03 (-6.06, -
0.01)*
75·0 (12·7) 73·4 (9·6) -1.55 (-4.94, 
1.85)*
73·1 (8·6) 67·8 (9·8) -5.29 (-8.55, -
2.03)*
Fasting bloods
HbA1c (mmol/mol) 56·3 (10·1) 55·2 (11·6) -0.50 (-6.00, 1.00) 57·8 (12·1) 56·6 (12·3) -1.00 (-3.07, 1.07) 54·8 (11·9) 44·4 (7·6) -7.50 (-13.34, -
5.00)
HbA1c (%) 7·3 (0·9) 7·2 (1·1) 0.00 (-0.59, 0.10) 7·4 (1·1) 7·3 (1·1) -0.10 (-0.31, 0.20) 7·2 (1·1) 6·2 (0·7) -0.75 (-1.23, -
0.40)
Glucose (mmol/L) 7·3 (6·7 - 9·1) 7·6 (6·3 - 9·0)  -0.19 (-0.97, 
0.60)*
8·2 (7·2 - 10·1) 7·7 (6·4 - 9·0) -0.82 (-1.59, -
0.05)*
7·1 (6·4 - 10·0) 6·3 (5·2 - 7·3) -1.89 (-2.78, -
1.00)*
Insulin (miu/L) 21·5 (14·4 - 
28·7)
18·5 (11·2 - 
32·5)
0.07 (-5.83, 
5.96)*
26·2 (19·2 - 
35·4)
20·0 (14·3 - 
41·4)
-3.79 (-9.92, 
2.34)*
29·2 (25·1 - 
38·1)
16·2 (11·7 - 
19·0)
-16.15 (-21.89, -
10.40)*
HOMA-IR 7·8 (4·7 - 9·3) 6·6 (3·3 - 11·7) -0.81 (-2.07, 
2.03)
9·8 (6·6 - 14·3) 6·5 (4·5 - 13·8) -2.91 (-4.98, 
0.39)
10·3 (8·0 - 13·6) 4·3 (3·0 - 6·0) -5.98 (-9.48, -
3.44)
Adiponectin 
(ng/mL)
4121·3 (3090·1 - 
7550·2)
4006·9 (2417·5 - 
6865·8)
17.81 (-795.87, 
515.42)
3043·2 (2435·4 
- 4169·0)
2767·5 (2186·9 
- 3495·9)
-354.54 (-815.60, 
256.48)
3714·4 (2546·3 - 
4681·7)
4764·1 (3158·4 - 
6159·5)
774.33 (-98.58, 
2,784.91)
Leptin (pg/mL) 19606·6 (9617·2 
- 34115·0)
18112·9 (8544·5 
- 27105·2)
-2,035.80 (-
4,300.81, -
559.33)
16831·1 
(11403·0 - 
23753·9)
12691·9 
(10098·3 - 
21983·9)
-526.05 (-
2,736.59, 
2,248.05)
19294·6 (9808·7 
- 51040·7)
6413·1 (3337·4 - 
20558·8)
-9,873.31 (-
13,360.80, -
5,803.63)
BNP (ng/L) 9·4 (4·4 - 15·7) 8·3 (4·8  14·4) 0.00 (-1.43, 2.89) 7·4 (2·7 - 18·0) 7·5 (3·5 - 16·4) 1.05 (-3.91, 4.26) 10·8 (5·0 - 15·1) 13·6 (5·0 - 24·3) 3.45 (0.73, 
8.61)
Cardiopulmonary exercise testing
Peak VO2 
(mL/Kg/min)
16·7 (3·7) 16·2 (4·1) -0.54 (-1.55, 
0.47)*
17·2 (4·5) 18·2 (4·9) 0.97 (-0.46, 2.40)* 16·4 (4·5) 18·3 (5·5) 1.93 (0.64, 
3.23)*
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Peak VO2 (L/min) 1·72 (0·48) 1·63 (0·51) -0.09 (-0.18, 
0.01)*
1·67 (0·50) 1·73 (0·52) 0.06 (-0.08, 0.20)* 1·72 (0·45) 1·67 (0·46) -0.05 (-0.16, 
0.06)*
Total exercise 
duration (mins:secs)
11·3 (2·2) 11·1 (2·2) -0.15 (-0.60, 0.25) 10·6 (2·3) 11·8 (3·1) 1.20 (0.17, 2.07) 11·4 (2·2) 11·2 (1·7) -0.37 (-0.62, 
0.47)
Maximum workload 
(W)
123·0  (41·9) 122·0  (47·3) -2.50 (-8.74, 3.00) 123·2  (47·1) 141·3 (54·9) 22.00 (5.81, 
32.00)
132·5 (56·4) 132·3 (50·1) -3.50 (-9.34, 
10.01)
Data are n (%), median (IQR) or mean (SD), and median change (95% confidence interval). *Data are mean change (95% confidence interval). 
BP=blood pressure. RAAS=renin angiotensin aldosterone system. GLP-1=glucagon-like peptide-1. DPP-IV=dipeptidyl peptidase-IV. SGLT-
2=sodium glucose cotransporter-2.  HOMA-IR=homeostatic model assessment of insulin resistance. BNP=brain natriuretic peptide.
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Table 3. Cardiac magnetic resonance imaging and echocardiography data at baseline and 12 weeks in the three trial arms.
Routine care (n=30) Exercise (n=22) MRP (n=24)
Baseline Week 12 Mean change (95% 
CI)
Baseline Week 12 Mean change 
(95% CI)
Baseline Week 12 Mean change 
(95% CI)
Cardiovascular magnetic resonance imaging
LV PEDSR (s-1) 1·06 (0·15) 0·98 (0·18) -0.07 (-0.13, -0.02) 0·92 (0·20) 1·02 (0·17)* 0.10 (0.04, 0.16) 1·00 (0·21) 0·96 (0·23) -0.05 (-0.13, 0.03)
LV global longitudinal 
strain (%)
-17·4 (2·2) -16·8 (1·8) 0.63 (-0.16, 1.41) -16·3 (2·9) -16·1 (2·5) 0.23 (-0.79, 
1.25)
-16·6 (2·9) -16·0 (1·8) 0.61 (-0.51, 1.72)
LV mass (g) 116·1 (22·8) 117·0 (24·2) 0.90 (-2.93 to 4.73) 123·1 (21·9) 122·0 (20·9) -1.15 (-6.73, 
4.44)
131·2 (26·9) 125·6 (27·0) -5.56 (-11.53 to 
0.40)
LV mass/volume 0·82 (0·77 - 0·86) 0·83 (0·77 - 0·92) 0.02 (-0.01, 0.05) 0·86 (0·75 - 
0·91)
0·85 (0·76 - 0·88) -0.02 (-0.06, 
0.02)
0·80 (0·74 - 
0·91)
0·79 (0·72 - 
0·87)
-0.03 (-0.06 to -
0.01)
LV EDV (mL) 133·9 (125·3 - 
148·8)
128·7 (117·4 - 
149·6)
-0.37 (-4.75, 4.00) 147·2 (129·3 - 
161·3)
145·1 (132·0 - 
159·7)
2.45 (-4.36, 
9.27)
172·5 (131·7 - 
180·7)
172·3 (116·3 - 
188·9)
-0.15 (-5.90 to 
5.60)
LV EDVi (mL/m2) 63·3 (58·1 - 67·8) 61·5 (56·3 - 69·0) 0.46 (-1.79, 2.72) 67·4 (62·0 - 
70·6)
66·1 (62·9 - 72·4) 1.50 (-1.53, 
4.52)
71·6 (59·9 - 
78·4)
77·9 (64·3 - 
87·5)
4.97 (2.22 to 7.73)
LV EF (%) 67·6 (5·4) 66·2 (5·3) -1.42 (-3.76, 0.92) 66·8 (7·9) 66·0 (6·2) -0.79 (-3.78, 
2.20)
69·8 (7·4) 65·2 (6·1) -4.54 (-6.89 to -
2.18)
Myocardial perfusion 
reserve
2·7 (0·8) 3·2 (1·1) 0.49 (-0.03, 1.00) 3·3 (0·9) 3·4 (1·2) 0.10 (-0.54, 
0.75)
3·0 (1·1) 3·2 (0·9) 0.18 (-0.44, 0.79)
Aortic distensibility 
(mmHg-1x10-3)
3.7 (2.9  5.5) 4·8 (3·0  5·8)
0.51 (-0.20, 1.21)
3.3 (2·7  5·7) 3·8 (2·9 - 4·6)
0.55 (-0.87, 
1.97)
3·2 (2·3  4·3) 4·2 (3·1  6·1)
0.90 (0.38, 1.41)
Echocardiography
Average E/e' 8·0 (6·5  9·7) 8·6 (7·1  9·3) 0.18 (-0.49, 0.85) 8·8 (7·0  10·6) 8·1 (6·8  9·3) -0.70 (-1.78, 
0.39)
10·1 (7·5 - 11·0) 8·5 (7·6  9·7) -0.67 (-1.83, 0.48)
Average E/A 1·00 (0·21) 1·01 (0·25) 0.01 (-0.06, 0.09) 0·94 (0·19) 1·00 (0·21) 0.06 (-0.03, 
0.15)
0·92 (0·20) 0·99 (0·23) 0.07 (-0.03, 0.17)
Data are mean (SD) or median (IQR), and mean (95% confidence interval). MRP=meal replacement plan. LV=left ventricle. PEDSR=peak early 
diastolic strain rate. BSA=body surface. EDV=end diastolic volume. EDVi=end diastolic volume indexed to body surface area. ESV=end 
systolic volume. ESVi=end systolic volume indexed to body surface area. EF=ejection fraction. 
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Figure legends
Figure 1. Box plots displaying change in left ventricular peak early diastolic strain 
rate (LV PEDSR) from baseline to 12 weeks in the three trial arms. *denotes 
statistical significance. 
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260	T2Ds	assessed	for	
eligibility	
90	randomised	
93	enrolled	
30	assigned	rou7ne	care	 29	assigned	MRP	
30	completed	rou2ne	
care	
31	assigned	exercise	
2	ineligible	
7	discon7nued	treatment	
										6	noncompliant	
										1	inves7gator	decision	
	
1	ineligible	
4	discon7nued	treatment		
											2	noncompliant	
											2	withdrew	consent	
											
	
167	excluded	
	130	ineligible	
	 	13	diabetes	dura7on	>12y	
	 	33	BMI	<30	or	<27kg/m2	
	 	7	insulin	treatment	
	 	11	HbA1c	>11%	
	 	7	cardiovascular	disease	
	 	59	other	
	21	withheld	consent	
	16	other	
	
3	ineligible	
22	completed	exercise	 24	completed	MRP	
39	controls	assessed	for	
eligibility	
	
3	excluded	
												1	ineligible	
	BMI	>30	or	27kg/m2	
												2	claustrophobia	
	 		
36	controls	included	
Supplementary	Figure	1.	Trial	pro)ile.	Abbreviations:	T2D=type	2	diabetes	mellitus;	MRP=meal	replacement	plan.	
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